12 Feb 2018 Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
10 Feb 2018 BeiGene Presents Preliminary Phase 1 Data on Tislelizumab in Patients with Urothelial Carcinoma at 2018 Genitourinary Cancers Symposium
09 Feb 2018 ArmaGen's AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I
09 Feb 2018 WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development
09 Feb 2018 Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial
08 Feb 2018 Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
07 Feb 2018 Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
07 Feb 2018 Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
06 Feb 2018 Grifols HyperRAB® (rabies immune globulin [human]) 300 IU/mL Receives FDA Approval to Treat Patients Exposed to Rabies Virus Infection
06 Feb 2018 Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
06 Feb 2018 Acticor Biotech Completed Its Phase I Clinical Trial with ACT017 Achieving Its Safety and Tolerability Primary Endpoints
06 Feb 2018 Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus Yervoy Combination Versus Chemotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with High Tumor Mutation Burden (TMB)
06 Feb 2018 Phase III IMmotion151 Study Showed Genentech’s TECENTRIQ (Atezolizumab) and Avastin (Bevacizumab) Reduced the Risk of Disease Worsening or Death by 26 Percent in Certain People with Advanced Kidney Cancer
04 Feb 2018 European Medicines Agency (EMA) Accepts Fremanezumab Marketing Authorization Application
01 Feb 2018 PharmAbcine Enters Collaboration with MSD Focused on Clinical Evaluation of TTAC-0001 in Combination with KEYTRUDA® (pembrolizumab) in Recurrent Glioblastoma and Breast Cancer
01 Feb 2018 Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca
01 Feb 2018 Affimed Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas
31 Jan 2018 BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Esophageal Squamous Cell Carcinoma
31 Jan 2018 Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
31 Jan 2018 Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
30 Jan 2018 WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Successful IND Filing for AVB-S6-500
30 Jan 2018 Innate Pharma and MedImmune enter clinical trial collaboration
29 Jan 2018 China Oncology Focus Limited Receives Approval by Chinese Authorities to Begin Clinical Trials in Three Separate Cancer Indications Using Sorrento’s Anti-PD-L1 Monoclonal Antibody
29 Jan 2018 Chugai's HEMLIBRA® Gains Positive CHMP Opinion in Hemophilia A with Inhibitors
27 Jan 2018 Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing